Petrichor Healthcare Capital Management

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

Leukocare is a biotechnology company focused on biopharmaceutical formulation development, specifically aimed at reducing systemic inflammation in patients undergoing cardiac surgery. The company specializes in protein stabilizing technologies that leverage bioinformatics and artificial intelligence to enhance the formulation of biopharmaceuticals, viral vectors, and vaccines. Additionally, Leukocare develops biofunctionalized devices designed to minimize leukocyte activity in extracorporeal blood circuits using targeted antibodies. By integrating advanced formulation techniques with cutting-edge technology, Leukocare aims to improve patient outcomes and ensure safer surgical procedures.

Leukocare is a biotechnology company focused on biopharmaceutical formulation development, specifically aimed at reducing systemic inflammation in patients undergoing cardiac surgery. The company specializes in protein stabilizing technologies that leverage bioinformatics and artificial intelligence to enhance the formulation of biopharmaceuticals, viral vectors, and vaccines. Additionally, Leukocare develops biofunctionalized devices designed to minimize leukocyte activity in extracorporeal blood circuits using targeted antibodies. By integrating advanced formulation techniques with cutting-edge technology, Leukocare aims to improve patient outcomes and ensure safer surgical procedures.

ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies. ITM’s isotope business is profitable and growing. In July 2016 the European Commission has granted Marketing Authorization for EndolucinBeta® of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and is used in Targeted Radionuclide Therapy. The drug approval is an important milestone for ITM as a specialized radiopharmaceutical company. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

ClearPoint Neuro, Inc. is a medical device company based in the United States that focuses on developing and commercializing platforms for minimally invasive surgical procedures guided by magnetic resonance imaging (MRI). The company's flagship product, the ClearPoint system, facilitates the precise insertion of catheters, electrodes, and laser fibers for treating various neurological conditions and conducting biopsies. ClearPoint Neuro also has a pipeline that includes the ClearTrace system, which aims to enable catheter-based procedures in the heart within an MRI suite. The company collaborates with notable institutions, including The Johns Hopkins University and the Mayo Clinic, to advance MRI-guided therapies, particularly for stroke. Founded in 1998 and headquartered in Irvine, California, ClearPoint Neuro was previously known as MRI Interventions until its name change in February 2020.

ClearPoint Neuro, Inc. is a medical device company based in the United States that focuses on developing and commercializing platforms for minimally invasive surgical procedures guided by magnetic resonance imaging (MRI). The company's flagship product, the ClearPoint system, facilitates the precise insertion of catheters, electrodes, and laser fibers for treating various neurological conditions and conducting biopsies. ClearPoint Neuro also has a pipeline that includes the ClearTrace system, which aims to enable catheter-based procedures in the heart within an MRI suite. The company collaborates with notable institutions, including The Johns Hopkins University and the Mayo Clinic, to advance MRI-guided therapies, particularly for stroke. Founded in 1998 and headquartered in Irvine, California, ClearPoint Neuro was previously known as MRI Interventions until its name change in February 2020.

Persivia Inc. is a healthcare IT company based in Marlborough, Massachusetts, that specializes in population health management solutions for hospitals, payers, and providers. Founded in 2005, the company offers an AI-driven platform designed to manage multiple value-based care programs, integrating clinical, socioeconomic, and claims data to create a comprehensive view of patient care. This platform supports various functions, including value-based care contract management, quality reporting, care coordination, chronic care management, and clinical analytics, particularly for Accountable Care Organizations (ACOs) and Patient-Centered Medical Homes (PCMH). Persivia's technology aims to improve patient outcomes by providing real-time clinical decision support and insights that help healthcare providers navigate regulations and manage population health risks effectively.

CorneaGen innovates cornea care, from new medical devices and biologics to therapeutics and interventions. CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovative products, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies.

CorneaGen innovates cornea care, from new medical devices and biologics to therapeutics and interventions. CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovative products, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies.